Get the Stockscreener App
0.3021
25.04%
-0.1009
After Hours:
.33
0.0279
+9.24%
Medicus Pharma Ltd stock is traded at $0.3021, with a volume of 50.30M.
It is down -25.04% in the last 24 hours and down -44.63% over the past month.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.
See More
Previous Close:
$0.403
Open:
$0.42945
24h Volume:
50.30M
Relative Volume:
11.42
Market Cap:
$11.89M
Revenue:
-
Net Income/Loss:
$-27.04M
P/E Ratio:
-0.153
EPS:
-1.9743
Net Cash Flow:
$-17.53M
1W Performance:
-35.21%
1M Performance:
-44.63%
6M Performance:
-86.81%
1Y Performance:
-91.72%
1-Day Range:
$0.29
$0.446
1-Week Range:
$0.29
$0.4664
52-Week Range:
$0.29
$8.94
Medicus Pharma Ltd Stock (MDCX) Company Profile
Name
Medicus Pharma Ltd
Sector
Industry
Phone
610-540-7515
Address
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
Compare MDCX vs LLY, JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
0.3021 | 15.86M | 0 | -27.04M | -17.53M | -1.9743 |
LLY
Lilly Eli Co
|
905.03 | 824.12B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
238.67 | 578.31B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
208.42 | 371.90B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
201.21 | 316.96B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
117.90 | 296.29B | 64.93B | 18.26B | 12.36B | 7.2751 |
Medicus Pharma Ltd Stock (MDCX) Latest News
Small cap wrap: Power Metallic Mines, EnWave, Sonoro Gold, Medicus Pharma… - Proactive financial news
Medicus Pharma Showcases Long-Acting Teverelix Data, Targets Precision Endometriosis Therapy - TipRanks
Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone ... - Caledonian Record
Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression - GlobeNewswire
EXCLUSIVE: Penny Stock Medicus Pharma Findings Support Potential In Women's Health Pipeline - Benzinga
Medicus Pharma on Bloomberg World - Monroe Evening News
Medicus Pharma to present new Teverelix data at upcoming endocrinology meeting - Yahoo Finance
EPS Watch: What is the dividend yield of Medicus Pharma Ltd Equity WarrantEarnings Risk Summary & Technical Confirmation Trade Alerts - baoquankhu1.vn
Aug Weekly: Can Medicus Pharma Ltd Equity Warrant disrupt its industryWeekly Market Summary & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
US Stocks Recap: Is Medicus Pharma Ltd Equity Warrant subject to activist investor interestForecast Cut & Low Risk Investment Opportunities - baoquankhu1.vn
New to The Street to Broadcast on Fox Business on Monday, April 13, Featuring Virtuix Holdings (NASDAQ:VTIX), Medicus Pharma (NASDAQ - marketscreener.com
New to The Street to Broadcast on Fox Business on Monday, April 13, Featuring Virtuix Holdings (NASDAQ:VTIX), Medicus Pharma (NASDAQ:MDCX), YY Group Holdings (NASDAQ:YYGH), Vivos Therapeutics (NASDAQ:VVOS), and Stardust Power (NASDAQ - Moomoo
Medicus Pharma gives Teverelix Phase 2 FDA update – ICYMI - Proactive financial news
MDCX Forecast, Price Target & Analyst Ratings | MEDICUS PHARMA LTD (NASDAQ:MDCX) - ChartMill
New to The Street Signs Medicus Pharma Ltd. (NASDAQ:MDCX) to Transformational 12-Part National Media Series Highlighting SkinJect(TM) and Teverelix(R) Platforms - ACCESS Newswire
Medicus Clarifies Phase 2 Results for SkinJect Cancer Therapy - MyChesCo
Medicus Pharma Ltd. (MDCX) stock price, news, quote and history - Yahoo Finance Australia
Medicus Pharma Submits Phase 2 Protocol for Teverelix to FDA - MyChesCo
Medicus Pharma Ltd (MDCX) Stock Price, Quote, News & History - Benzinga
Medicus Pharma submits optimized Phase 2 study design for Teverelix - Proactive financial news
Market movers: Virgin Galactic, Soleno Therapeutics, Medicus Pharma... - Proactive financial news
Medicus Pharma Streamlines Phase 2 Teverelix Trial for $2 Billion AUR Market - TipRanks
Medicus Pharma submits optimized Phase 2 Teverelix trial protocol to FDA - Yahoo Finance
Medicus targets recurrent urinary retention with 126-patient study - Stock Titan
EXCLUSIVE: Medicus Pharma Refines Trial Design To Cut Costs, Accelerate Development For Enlarged Prostate - Benzinga
EXCLUSIVE: Medicus Pharma Refines Trial Design To Cut Costs, Accelerate Development For Enlarged Prostate Patients - Sahm
Medicus Pharma submits optimized Phase 2 protocol for Teverelix - grafa.com
Medicus Pharma SkinJect Phase 2 study data endorsed by independent expertICYMI - Proactive financial news
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony - gosanangelo.com
Medicus Pharma stock swings after skin cancer treatment results - MSN
Medicus Pharma clarifies Phase 2 skin cancer study results By Investing.com - Investing.com South Africa
MDCX SEC FilingsMedicus Pharma Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Medicus Pharma (MDCX) COO granted 50,000 options at $0.50 exercise price - Stock Titan
Director at Medicus Pharma (NASDAQ: MDCX) awarded 25,000 stock options at $0.50 - Stock Titan
Director at Medicus Pharma (NASDAQ: MDCX) receives 25,000 stock options at $0.50 strike - Stock Titan
CMO at Medicus Pharma (MDCX) receives 125,000 stock options grant - Stock Titan
[Form 4] Medicus Pharma Ltd. Insider Trading Activity - Stock Titan
Medicus Pharma (MDCX) director granted stock options for 25,000 Common Shares - Stock Titan
Director Barry Fishman granted 25,000 Medicus Pharma (MDCX) stock options - Stock Titan
Medicus Pharma (MDCX) grants director 25K stock options at $0.50 - Stock Titan
Medicus Pharma (MDCX) Chief Scientific Officer receives 25,000 stock options grant - Stock Titan
MDCXW SEC FilingsMedicus Pharma Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Medicus Pharma (NASDAQ: MDCX) CEO awarded 325,000 options at $0.50 strike - Stock Titan
Medicus Pharma (NASDAQ: MDCX) director receives grant of 25,000 options at $0.50 strike - Stock Titan
Medicus Pharma gains independent validation for SkinJect Phase 2 data - Proactive financial news
Medicus Pharma eyes registrational study for SkinJect after positive Phase 2 data - Yahoo Finance
Medicus Pharma Ltd clarifies positive Skinject phase 2 dataset - marketscreener.com
Medicus Pharma Ltd Clarifies Positive Skinject Phase 2 Dataset - TradingView
Medicus Pharma Ltd Stock (MDCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Medicus Pharma Ltd Stock (MDCX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| VELOCITY FUND PARTNERS, LP | 10% Owner |
May 20 '25 |
Sale |
7.72 |
75,000 |
578,940 |
3,248,741 |
0.30%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):